Cipla Gets CGT Nod For US Migranal Rival
FDA Approval With CGT Designation Comes With 180-Day Exclusivity
Executive Summary
Cipla’s generic equivalent of Migranal is the company’s first nasal spray to receive FDA approval, accompanied by 180 days of competitive generic therapy exclusivity.
You may also be interested in...
Cipla’s Proventil Rival Gnaws At US Market
Cipla’s generic of Merck & Co’s Proventil makes significant inroads in the US, with the Indian company confident that it has both a strong cost position and large capacity to take on competition. Pricing in the segment currently remains ‘respectable.’
Cipla’s Proventil Generic Gnaws At US Market
Cipla’s generic of Merck & Co’s Proventil makes significant inroads in the US, with the Indian company confident that it has both a strong cost position and large capacity to take on competition. Pricing in the segment currently remains ‘respectable’.
Cipla Propels 'Lung Leadership' Plans
Cipla’s fourth-quarter 2020 sales were hit because of COVID-19- related dispatch challenges, though it remains upbeat about the prospects of interchangeable albuterol and the latest filing for generic Advair Diskus as part of its quest for lung leadership.